evaluation of the relationship between factor ix inhibitor in hemophilia b patients and different types of therapy in the north-eastern part of iran

background: hemophilia b is a bleeding disorder with a recessive x-linked inheritance pattern, in which the infected individuals have low levels of factor ix in their plasma. affected individuals may have bleeding episodes after trauma or spontaneously considering the plasma level of factor ix. in order to prevent these episodes and to control bleeding, they should use coagulation factor concentrates that may be associated with the formation of inhibitors. methods: this study was conducted in the northeast of iran in 2006. among 48 individuals who agreed to participate in our survey, 3 individuals (6.25%) had used ffp, 38 s (79.16%) factor ix concentrate and 7 (14.58 both ffp and factor ix concentrate in the 6 months prior to the study. of them, three participants (6.3%) had factor ix inhibitor which was assayed using bethesda method. results: three hemophilia b (6.3%) patients had factor ix inhibitor, but no correlation was found between the existence of the inhibitor and the type of coagulation therapy. conclusion: our findings did not show any correlation between factor ix inhibitor and type of coagulation therapy used in the 6 month period (p=0.65). none of the hemophiliacs had used coagulation factor as a prophylaxis regimen and most of them (83.33%) had injected coagulation factor on demand.